Free Deal Calculator

Calculate ADC Deal Valuations in Minutes

Get market-accurate licensing estimates for antibody-drug conjugates with real-time data from billion-dollar deals

Market-Leading ADC Data

Built on analysis of $50B+ in recent ADC deals including Daiichi acquisitions. Our models reflect the current 45% premium ADCs command over traditional assets.

Instant Valuation Range

Generate Phase 2 upfront estimates ($60M-$250M) and total deal projections ($700M-$2.5B) in under 2 minutes versus weeks of manual analysis.

Investor-Grade Accuracy

Validated against 200+ completed ADC transactions with BD-ready outputs that pass due diligence scrutiny from top pharma partners.

$2.5B

Max ADC Deal Value

45%

Current Market Premium

200+

Deals Benchmarked

95%

Accuracy Rate

How It Works

Input ADC Parameters

Enter your payload type, linker technology, development stage, and target indication to establish baseline valuation factors.

Apply Market Premiums

Our algorithm automatically adjusts for current ADC market dynamics, including the 45% hot market premium and indication-specific multiples.

Get Deal Structure

Receive upfront, milestone, and royalty ranges plus comparable deal benchmarks formatted for term sheet negotiations.

Frequently Asked Questions

Why are ADC deals valued higher than traditional antibodies?

ADCs combine targeted delivery with potent payloads, creating differentiated assets. Recent Daiichi successes with Enhertu have driven a 45% valuation premium as pharma seeks next-generation oncology platforms.

What ADC deal data does the calculator use?

We analyze 200+ completed ADC transactions including recent mega-deals like AstraZeneca-Daiichi ($6.9B), Gilead-Immunomedics ($21B), and Pfizer-Seagen ($43B) to ensure current market accuracy.

How accurate are the Phase 2 upfront estimates?

Our Phase 2 ADC upfront range ($60M-$250M) reflects actual completed deals with 95% accuracy. The wide range accounts for payload novelty, target validation, and competitive landscape factors.

Can I use this for investor presentations?

Yes. Our outputs include comparable deal benchmarks, valuation methodology, and market context suitable for board decks, investor updates, and BD negotiations with pharma partners.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating